2 research outputs found
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes
Human immunodeficiency virus type 1 (HIV-1) tropism can be assessed using phenotypic assays, but this is
quite laborious, expensive, and time-consuming and can be made only in sophisticated laboratories. More
accessible albeit reliable tools for testing of HIV-1 tropism are needed in view of the prompt introduction of
CCR5 antagonists in clinical practice. Bioinformatics tools based on V3 sequences might help to predict HIV-1
tropism; however, most of these methods have been designed by taking only genetic information derived from
HIV-1 subtype B into consideration. The aim of this study was to evaluate the performances of several
genotypic tools to predict HIV-1 tropism in non-B subtypes, as data on this issue are scarce. Plasma samples
were tested using a new phenotypic tropism assay (Phenoscript-tropism; Eurofins), and results were compared
with estimates of coreceptor usage using eight different genotypic predictor softwares (Support Vector Machine
[SVM], C4.5, C4.5 with positions 8 to 12 only, PART, Charge Rule, geno2pheno coreceptor, Position-Specific
Scoring Matrix X4R5 [PSSMX4R5], and PSSMsinsi). A total of 150 samples were tested, with 115 belonging
to patients infected with non-B subtypes and 35 drawn from subtype B-infected patients, which were taken
as controls. When non-B subtypes were tested, the concordances between the results obtained using the
phenotypic assay and distinct genotypic tools were as follows: 78.8% for SVM, 77.5% for C4.5, 82.5% for
C4.5 with positions 8 to 12 only, 82.5% for PART, 82.5% for Charge Rule, 82.5% for PSSMX4R5, 83.8% for
PSSMsinsi, and 71.3% for geno2pheno. When clade B viruses were tested, the best concordances were seen
for PSSMX4R5 (91.4%), PSSMsinsi (88.6%), and geno2pheno (88.6%). The sensitivity for detecting X4
variants was lower for non-B than for B viruses, especially in the case of PSSMsinsi (38.4% versus 100%,
respectively), SVMwetcat (46% versus 100%, respectively), and PART (30% versus 90%, respectively). In
summary, while inferences of HIV-1 coreceptor usage using genotypic tools seem to be reliable for clade
B viruses, their performances are poor for non-B subtypes, in which they particularly fail to detect X4
variants
Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model
Two recombinant phenotypic assays for human immunodeficiency virus (HIV) coreceptor usage and an HIV envelope genotypic predictor were employed on a set of clinically derived HIV type 1 (HIV-1) samples in order to evaluate the concordance between measures. Previously genotyped HIV-1 samples derived from antiretroviral-naïve individuals were tested for coreceptor usage using two independent phenotyping methods. Phenotypes were determined by validated recombinant assays that incorporate either an ∼2,500-bp (“Trofile” assay) or an ∼900-bp (TRT assay) fragment of the HIV envelope gp120. Population-based HIV envelope V3 loop sequences (∼105 bp) were derived by automated sequence analysis. Genotypic coreceptor predictions were performed using a support vector machine model trained on a separate genotype-Trofile phenotype data set. HIV coreceptor usage was obtained from both phenotypic assays for 74 samples, with an overall 85.1% concordance. There was no evidence of a difference in sensitivity between the two phenotypic assays. A bioinformatic algorithm based on a support vector machine using HIV V3 genotype data was able to achieve 86.5% and 79.7% concordance with the Trofile and TRT assays, respectively, approaching the degree of agreement between the two phenotype assays. In most cases, the phenotype assays and the bioinformatic approach gave similar results. However, in cases where there were differences in the tropism results, it was not clear which of the assays was “correct.” X4 (CXCR4-using) minority species in clinically derived samples likely complicate the interpretation of both phenotypic and genotypic assessments of HIV tropism